Cetuximab chemotherapy resistance: Insight into the homeostatic evolution of head and neck cancer (Review)

Oncol Rep. 2024 Jun;51(6):80. doi: 10.3892/or.2024.8739. Epub 2024 Apr 19.

Abstract

The complex evolution of genetic alterations in cancer that occurs in vivo is a selective process involving numerous factors and mechanisms. Chemotherapeutic agents that prevent the growth and spread of cancer cells induce selective pressure, leading to rapid artificial selection of resistant subclones. This rapid evolution is possible because antineoplastic drugs promote alterations in tumor‑cell metabolism, thus creating a bottleneck event. The few resistant cells that survive in this new environment obtain differential reproductive success that enables them to pass down the newly selected resistant gene pool. The present review aims to summarize key findings of tumor evolution, epithelial‑mesenchymal transition and resistance to cetuximab therapy in head and neck squamous cell carcinoma.

Keywords: cetuximab; drug resistance; epithelial‑mesenchymal transition; head and neck neoplasms; tumor evolution.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Carcinoma, Squamous Cell* / genetics
  • Cell Line, Tumor
  • Cetuximab / pharmacology
  • Cetuximab / therapeutic use
  • Drug Resistance, Neoplasm / genetics
  • Head and Neck Neoplasms* / drug therapy
  • Head and Neck Neoplasms* / genetics
  • Humans

Substances

  • Cetuximab

Grants and funding

This review was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Pesquisas (CNPq) grant (grant no. FAPESP 18/15468-1/EHT) and fellowships (grant nos. FAPESP 2021/03647-1/CHDP, FAPESP 2019/07293-0/TBC, FAPESP 2021/07087-0/TBC, CNPq 140107/2015-0/ACBS and CNPq 307327/2018-3/EHT).